Certara (NASDAQ:CERT) Given New $12.00 Price Target at Barclays

Certara (NASDAQ:CERT) had its target price lowered by Barclays from $14.00 to $12.00 in a report published on Thursday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

A number of other research analysts have also recently commented on the company. KeyCorp reduced their target price on Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Friday, September 27th. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Finally, Robert W. Baird reduced their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.92.

Certara Trading Up 0.4 %

Certara stock opened at $11.03 on Thursday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61. Certara has a fifty-two week low of $9.99 and a fifty-two week high of $19.87. The stock has a market cap of $1.78 billion, a P/E ratio of -55.15, a PEG ratio of 5.20 and a beta of 1.51. The firm’s fifty day moving average price is $11.02 and its 200-day moving average price is $13.66.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter last year, the firm posted $0.06 EPS. The company’s revenue was up 10.7% compared to the same quarter last year. Equities research analysts forecast that Certara will post 0.27 earnings per share for the current fiscal year.

Insider Transactions at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now owns 99,704 shares in the company, valued at $1,125,658.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Certara

Several hedge funds have recently made changes to their positions in the company. Landscape Capital Management L.L.C. purchased a new stake in shares of Certara in the 3rd quarter worth about $852,000. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Certara during the third quarter valued at approximately $1,513,000. Quest Partners LLC bought a new stake in shares of Certara in the 3rd quarter worth approximately $367,000. Zions Bancorporation N.A. grew its stake in shares of Certara by 18.5% in the 3rd quarter. Zions Bancorporation N.A. now owns 76,811 shares of the company’s stock worth $899,000 after buying an additional 11,995 shares during the last quarter. Finally, KBC Group NV increased its position in Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after buying an additional 1,584 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.